



Lantheus Holdings to Present at the BMO Prescriptions for Success Healthcare Conference

November 28, 2018

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 28, 2018-- [Lantheus Holdings, Inc.](#) (the "Company") (NASDAQ: LNTH), the parent company of [Lantheus Medical Imaging, Inc.](#) ("LMI"), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced Mary Anne Heino, President and Chief Executive Officer, will present at the BMO Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018 at 3:00 p.m. Eastern in New York City.

To access a live webcast of the presentation, please visit the [Investors section](#) of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for 30 days following the live presentation.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechnelLife® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181128005615/en/>

Source: Lantheus Holdings, Inc.

Meara Murphy
Director, Investor Relations & Corporate Communications
978-671-8508